Oncolytics Biotech Publishes Data On Pelareorep Immunotherapy In Proceedings Of The National Academy Of Sciences

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the publication of data regarding its investigational immunotherapy, pelareorep, in the Proceedings of the National Academy of Sciences. The study demonstrates pelareorep's potential to convert an immunologically inactive liver cancer tumor microenvironment into one that is active and responsive to immune-based therapies. The findings highlight the therapy's ability to enhance protective immune responses and promote the expansion of tumor-infiltrating lymphocytes.